Pancreatic Cancer Research

ResearcherJohns Hopkins UniversityNo recent work listed

Tatsuo Hata

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5155-2508; OpenAlex author ID A5000183608. Sources: OpenAlex.

Their work

Papers
19 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
61
Papers, trials and grants by year

2016: 1 paper · 2017: 1 paper · 2018: 2 papers · 2019: 3 papers · 2020: 5 papers · 2021: 4 papers · 2022: 2 papers · 2023: 1 paper

Papers 19

  1. Prognostic impact of postoperative circulating tumor DNA as a molecular minimal residual disease marker in patients with pancreatic cancer undergoing surgical … Co-author DOI 10.1002/jhbp.1282↗
  2. Levels of tumor markers CEA/CA 19-9 in serum and peritoneal lavage predict postoperative recurrence in patients with pancreatic cancer. Co-author DOI 10.1002/ags3.12597↗
  3. Impact of Tumor-Derived DNA Testing in Peritoneal Lavage of Pancreatic Cancer Patients with and Without Occult Intra-Abdominal Metastases. First author DOI 10.1245/s10434-021-10997-w↗
  4. Germline DNA damage repair gene mutations in pancreatic cancer patients with personal/family histories of pancreas/breast/ovarian/prostate cancer in a Japanese… Co-author DOI 10.1002/ags3.12482↗
  5. Circulating tumor DNA as a predictive marker for occult metastases in pancreatic cancer patients with radiographically non-metastatic disease. Co-author DOI 10.1002/jhbp.993↗
  6. Staging laparoscopy is mandatory for the treatment of pancreatic cancer to avoid missing radiologically negative metastases. Co-author DOI 10.1007/s00595-020-02121-4↗
  7. MicroRNA-593-3p Expression in Peritoneal Lavage Fluid as a Prognostic Marker for Pancreatic Cancer Patients Undergoing Staging Laparoscopy. Co-author DOI 10.1245/s10434-020-09440-3↗
  8. Methylation-mediated silencing of the LIM homeobox 6 (LHX6) gene promotes cell proliferation in human pancreatic cancer. Co-author DOI 10.1016/j.bbrc.2020.03.120↗
  9. Prognostic impact of intraoperative peritoneal cytology after neoadjuvant therapy for potentially resectable pancreatic cancer. Co-author DOI 10.1016/j.pan.2020.08.022↗
  10. Impact of resection margin status on survival in pancreatic cancer patients after neoadjuvant treatment and pancreatoduodenectomy. Co-author DOI 10.1016/j.surg.2019.12.008↗
  11. Epigenetic inactivation of IRX4 is responsible for acceleration of cell growth in human pancreatic cancer. Co-author DOI 10.1111/cas.14644↗
  12. Stromal expression of hemopexin is associated with lymph-node metastasis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1371/journal.pone.0235904↗
  13. Long-term outcome following neoadjuvant therapy for resectable and borderline resectable pancreatic cancer compared to upfront surgery: a meta-analysis of comp… First author DOI 10.1007/s00595-019-01786-w↗
  14. Collagen gel droplet-embedded culture drug sensitivity test (CD-DST) predicts the effect of adjuvant chemotherapy on pancreatic cancer. Co-author DOI 10.1007/s00595-019-01842-5↗
  15. [Conversion Surgery for Locally Advanced Unresectable Pancreatic Cancer Treated with FOLFIRINOX Therapy and Proton Beam Therapy Combined with S-1 Chemotherapy-… Co-author PMID 32157015↗
  16. Simple Detection of Telomere Fusions in Pancreatic Cancer, Intraductal Papillary Mucinous Neoplasm, and Pancreatic Cyst Fluid. Co-author DOI 10.1016/j.jmoldx.2017.09.006↗
  17. Mutations in the pancreatic secretory enzymes CPA1 and CPB1 are associated with pancreatic cancer. Co-author DOI 10.1073/pnas.1720588115↗
  18. A long-term survival case treated with conversion surgery following chemotherapy after diagnostic metastasectomy for pancreatic cancer with synchronous liver m… Co-author DOI 10.1186/s40792-017-0409-9↗
  19. Telomerase activity in pancreatic juice differentiates pancreatic cancer from chronic pancreatitis: A meta-analysis. Co-author DOI 10.1016/j.pan.2016.01.007↗

Closest collaborators

The 25 strongest of 61 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Michiaki Unno · 17 shared papers, 2016–2023 · strength 1.94
  2. Fuyuhiko Motoi · 16 shared papers, 2016–2023 · strength 1.82
  3. Masamichi Mizuma · 12 shared papers, 2017–2023 · strength 1.39
  4. Kei Nakagawa · 11 shared papers, 2017–2023 · strength 1.31
  5. Takanori Morikawa · 10 shared papers, 2017–2023 · strength 1.22
  6. Tatsuyuki Takadate · 7 shared papers, 2017–2022 · strength 0.69
  7. Kei Kawaguchi · 5 shared papers, 2019–2022 · strength 0.50
  8. Masahiro Iseki · 5 shared papers, 2017–2021 · strength 0.45
  9. Kazuharu Chiba · 3 shared papers, 2021–2022 · strength 0.42
  10. Shimpei Maeda · 4 shared papers, 2017–2021 · strength 0.34
  11. Kyohei Ariake · 4 shared papers, 2017–2021 · strength 0.34
  12. Shuichi Aoki · 3 shared papers, 2020–2022 · strength 0.33
  13. Toru Furukawa · 2 shared papers, 2021–2022 · strength 0.27
  14. Yakefujiang Abudurexiti · 2 shared papers, 2020 · strength 0.24
  15. Kanchan Chakma · 2 shared papers, 2020 · strength 0.24
  16. Shinichi Fukushige · 2 shared papers, 2020 · strength 0.24
  17. Akira Horii · 2 shared papers, 2020 · strength 0.24
  18. Mitsuhiro Shimura · 2 shared papers, 2017–2020 · strength 0.14
  19. Christopher Lee Wolfgang · 2 shared papers, 2018 · strength 0.14
  20. Michael Goggins · 2 shared papers, 2018 · strength 0.14
  21. James R. Eshleman · 2 shared papers, 2018 · strength 0.14
  22. Ralph H. Hruban · 2 shared papers, 2018 · strength 0.14
  23. Timothy R. Donahue · 1 shared paper, 2020 · strength 0.09
  24. Howard A. Reber · 1 shared paper, 2020 · strength 0.09
  25. Sean Patrick Cleary · 1 shared paper, 2020 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.